SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001493152-22-025258
Filing Date
2022-09-07
Accepted
2022-09-07 16:35:27
Documents
13
Period of Report
2022-09-07
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 38442
2 ex10-1.htm EX-10.1 78769
  Complete submission text file 0001493152-22-025258.txt   304011

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE eltp-20220907.xsd EX-101.SCH 2968
4 XBRL LABEL FILE eltp-20220907_lab.xml EX-101.LAB 34240
5 XBRL PRESENTATION FILE eltp-20220907_pre.xml EX-101.PRE 22365
7 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3392
Mailing Address 165 LUDLOW AVENUE NORTHVALE NJ 07647
Business Address 165 LUDLOW AVENUE NORTHVALE NJ 07647 2017502646
ELITE PHARMACEUTICALS INC /NV/ (Filer) CIK: 0001053369 (see all company filings)

IRS No.: 223542636 | State of Incorp.: NJ | Fiscal Year End: 0331
Type: 8-K | Act: 34 | File No.: 001-15697 | Film No.: 221231546
SIC: 2834 Pharmaceutical Preparations